Clinical Trial Search

Primary: Change in the Functional MRI Metrics Ktrans Between 2 Weeks and Baseline — 0.026 per minute (or min-1) — p=0.0016

Primary: Number of Participants Who Received CERE-120 Treatment — 3; 3; 24; 27 Participants

Primary: Serum VEGF-D — 0.05; 0.07 Log transformed VEGF-D change pg/dL

Primary: Drug Clearance — 0.71; 1.31 ml/min/kg

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: The Effect of Rhlactoferrin on Serum Levels of Interleukin-6 (IL-6) — -0.640; 0.932 Percent change of IL-6

Primary: Change in Haemoglobin Compared to the Baseline — 0.18; 0.54 g/dl

Primary: Number of Participants With Grade 3 or 4 Thrombocytopenia Occurring Within 30 Days After Initial Administration of Niraparib — 6 Participants

Primary: Phase I: Maximum-Tolerated Dose of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide (BOCE) — 120 mg/m^2

Primary: Unified Dyskinesia Rating Scale (UDysRS) — -4.2; -7.0 score on a scale

Primary: Change in Disease Severity — 23.3; 17.7 score on a scale — p=0.042

Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309

Primary: Bone Mineral Density of the Lumbar Spine as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan at 9 Months — -0.025; -0.086 g/cm2

Primary: Number of Subjects With Study Related Adverse Events. — 59 Participants